Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep;36(9):1409-1431.
doi: 10.1111/jdv.18345.

European guideline (EuroGuiDerm) on atopic eczema: part I - systemic therapy

A Wollenberg  1   2 , M Kinberger  3 , B Arents  4 , N Aszodi  1 , G Avila Valle  3 , S Barbarot  5 , T Bieber  6 , H A Brough  7   8 , P Calzavara Pinton  9 , S Christen-Zäch  10 , M Deleuran  11 , M Dittmann  3 , C Dressler  3 , A H Fink-Wagner  12 , N Fosse  13 , K Gáspár  14 , L Gerbens  15 , U Gieler  16 , G Girolomoni  17 , S Gregoriou  18 , C G Mortz  19 , A Nast  3 , U Nygaard  20 , M Redding  21 , E M Rehbinder  22 , J Ring  23 , M Rossi  24 , E Serra-Baldrich  25 , D Simon  26 , Z Z Szalai  27 , J C Szepietowski  28 , A Torrelo  29 , T Werfel  30 , C Flohr  31   32
Affiliations
Free article

European guideline (EuroGuiDerm) on atopic eczema: part I - systemic therapy

A Wollenberg et al. J Eur Acad Dermatol Venereol. 2022 Sep.
Free article

Abstract

The evidence- and consensus-based guideline on atopic eczema was developed in accordance with the EuroGuiDerm Guideline and Consensus Statement Development Manual. Four consensus conferences were held between December 2020 and July 2021. Twenty-nine experts (including clinicians and patient representatives) from 12 European countries participated. This first part of the guideline includes general information on its scope and purpose, the health questions covered, target users and a methods section. It also provides guidance on which patients should be treated with systemic therapies, as well as recommendations and detailed information on each systemic drug. The systemic treatment options discussed in the guideline comprise conventional immunosuppressive drugs (azathioprine, ciclosporin, glucocorticosteroids, methotrexate and mycophenolate mofetil), biologics (dupilumab, lebrikizumab, nemolizumab, omalizumab and tralokinumab) and janus kinase inhibitors (abrocitinib, baricitinib and upadacitinib). Part two of the guideline will address avoidance of provocation factors, dietary interventions, immunotherapy, complementary medicine, educational interventions, occupational and psychodermatological aspects, patient perspective and considerations for paediatric, adolescent, pregnant and breastfeeding patients.

Keywords: atopic dermatitis; atopic eczema.

PubMed Disclaimer

References

    1. Kaminski-Hartenthaler A, Meerpohl JJ, Gartlehner G et al. GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. Z Evid Fortbild Qual Gesundhwes 2014; 108: 413-420.
    1. Drucker AM, Ellis AG, Bohdanowicz M et al. Systemic immunomodulatory treatments for patients with atopic dermatitis: a systematic review and network meta-analysis. JAMA Dermatol 2020; 156: 659-667.
    1. Drucker AM. Systemic immunomodulatory treatments for atopic dermatitis: a living systematic review and network meta-analysis. 2020.
    1. Silverberg JI, Simpson EL, Armstrong AW, de Bruin-Weller MS, Irvine AD, Reich K. Expert perspectives on key parameters that impact interpretation of randomized clinical trials in moderate-to-severe atopic dermatitis. Am J Clin Dermatol 2022; 23: 1-11.
    1. Wollenberg A, Christen-Zäch S, Taieb A et al. ETFAD/EADV eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. J Eur Acad Dermatol Venereol 2020; 34: 2717-2744.